326 related articles for article (PubMed ID: 22045075)
1. The impact of iso-osmolar contrast use in emergent percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Kanei Y; Ayabe K; Ratcliffe J; Vales L; Nakra N; Friedman P; Fox J
J Invasive Cardiol; 2011 Nov; 23(11):448-50. PubMed ID: 22045075
[TBL] [Abstract][Full Text] [Related]
2. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
[TBL] [Abstract][Full Text] [Related]
3. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
[TBL] [Abstract][Full Text] [Related]
4. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
[TBL] [Abstract][Full Text] [Related]
5. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.
Kandula P; Shah R; Singh N; Markwell SJ; Bhensdadia N; Navaneethan SD
Nephrology (Carlton); 2010 Mar; 15(2):165-70. PubMed ID: 20470274
[TBL] [Abstract][Full Text] [Related]
6. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.
Marenzi G; Lauri G; Assanelli E; Campodonico J; De Metrio M; Marana I; Grazi M; Veglia F; Bartorelli AL
J Am Coll Cardiol; 2004 Nov; 44(9):1780-5. PubMed ID: 15519007
[TBL] [Abstract][Full Text] [Related]
7. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
Worasuwannarak S; Pornratanarangsi S
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention.
Liu Y; Tan N; Zhou YL; Chen YY; Chen JY; Chen J; Luo JF
J Nephrol; 2012; 25(3):332-40. PubMed ID: 21928234
[TBL] [Abstract][Full Text] [Related]
9. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
[TBL] [Abstract][Full Text] [Related]
11. Prediction of contrast-induced nephropathy in diabetics undergoing elective percutaneous coronary intervention: role of the ratio of contrast medium volume to estimated glomerular filtration rate.
Wang XC; Fu XH; Wang YB; Jia XW; Wu WL; Gu XS; Zhang J; Su JL; Hao GZ; Jiang YF; Fan WZ; Li SQ
Chin Med J (Engl); 2011 Mar; 124(6):892-6. PubMed ID: 21518598
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.
Li W; Fu X; Wang Y; Li X; Yang Z; Wang X; Geng W; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
Cardiology; 2012; 122(3):195-202. PubMed ID: 22854323
[TBL] [Abstract][Full Text] [Related]
14. Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction.
Lucreziotti S; Centola M; Salerno-Uriarte D; Ponticelli G; Battezzati PM; Castini D; Sponzilli C; Lombardi F
Int J Cardiol; 2014 Jun; 174(1):37-42. PubMed ID: 24698233
[TBL] [Abstract][Full Text] [Related]
15. Elevated admission serum creatinine predicts poor myocardial blood flow and one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Zhao L; Wang L; Zhang Y
J Invasive Cardiol; 2009 Oct; 21(10):493-8. PubMed ID: 19805833
[TBL] [Abstract][Full Text] [Related]
16. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
[TBL] [Abstract][Full Text] [Related]
17. Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention.
Marenzi G; De Metrio M; Rubino M; Lauri G; Cavallero A; Assanelli E; Grazi M; Moltrasio M; Marana I; Campodonico J; Discacciati A; Veglia F; Bartorelli AL
Am Heart J; 2010 Dec; 160(6):1170-7. PubMed ID: 21146674
[TBL] [Abstract][Full Text] [Related]
18. [Association between high-sensitivity C-reactive protein and contrast-induced nephropathy after primary percutaneous coronary intervention].
He YT; Tan N; Liu YH; Chen SQ; Liu Y; Huang SJ; Yang DH; Ye P; Ran P
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 May; 41(5):394-8. PubMed ID: 24021122
[TBL] [Abstract][Full Text] [Related]
19. [Risk factors and scoring system in the prediction of contrast induced nephropathy in patients undergoing percutaneous coronary intervention].
Fu NK; Yang SC; Chen YL; Xu J; Li Q; Li XM; Liu YY; Liu XG; Cong HL
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):551-4. PubMed ID: 22490160
[TBL] [Abstract][Full Text] [Related]
20. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
